BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference
(BMXX) Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) Presentation to Focus on Positive Topline Result...
Are there any regulatory or reimbursement challenges that could affect the timeline for BX211's onward development and market entry?
What is the expected commercial potential and market size for a therapy treating diabetic foot osteomyelitis compared to existing treatments?
How will the Phase 2 topline results for BX211 impact BMXX's revenue forecasts and valuation?
9 days ago